熱門資訊> 正文
Arcus Biosciences获得2.5亿美元定期贷款安排
2024-08-28 04:18
- Arcus Biosciences (NYSE:RCUS) reported it has obtained a $250M term loan facility from Hercules Capital.
- The additional capital strengthens Arcus’s balance sheet and increases flexibility to rapidly advance casdatifan, its potential best-in-class HIF-2a inhibitor.
- Arcus plans to present data from ARC-20, its Phase 1/1b study of casdatifan in clear cell renal cell carcinoma, later this year.
- Under the terms of the term loan facility, $50M was drawn at closing and an additional $100M is committed and fully available at Arcus’s sole option in minimum increments of $25M.
- Source: Press Release
More on Arcus Biosciences
- Arcus Biosciences: Getting Too Cheap To Ignore (Reiterate Buy)
- Arcus Biosciences, Inc. (RCUS) Q2 2024 Earnings Call Transcript
- Arcus Biosciences, Inc. 2024 Q2 - Results - Earnings Call Presentation
- Arcus Biosciences GAAP EPS of -$1.02 beats by $0.11, revenue of $39M beats by $12.51M
- Gilead, Arcus combo significantly reduces death risk in colorectal cancer
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
